Project area or title
Development of a tool to predict risk of cardiometabolic impairment with antipsychotic therapy: a personalised precision medicine approach
The average life expectancy of patients with psychosis is 15-20years less than general population, increased risk of cardiometabolic diseases is a major contributor. Antipsychotic medications, the mainstay treatment of psychosis increase risk of cardiometabolic illnesses. Risk depends on the medication used, combined with each individual’s response. We have preliminary data to show that we can precisely evaluate metabolic changes caused by specific antipsychotic medications through characterisation of mitochondrial metabolism by high resolution respirometry in different cell types.
This project aims to develop a tool to guide treatment choice for an individual patient to predict and prevent potential cardiometabolic effects.
Severe Mental Health
University of Nottingham